Dr. Raghunath Anant Mashelkar was the Director-General of the Council of Scientific and Industrial Research for over eleven years, and also served as the President of Indian National Science Academy.
He is only the third Indian engineer to have been elected as Fellow of Royal Society (FRS), London in the twentieth century. He was elected Foreign Associate of the US National Academy of Science in 2005, Foreign Fellow of US National Academy of Engineering in 2003 and Fellow of Royal Academy of Engineering, UK in 1996. Dr. Mashelkar has won over 50 awards and medals from several bodies for his outstanding contribution in the field of science and technology. He has been awarded honorary doctorates by 27 universities from across the world. He is the only scientist so far to have won the JRD Tata Corporate Leadership Award. In 2011, Dr. Mashelkar was named National Research Professor by the Government of India.
Venkat comes with a very rich and global experience of successfully leading organizations in the Life sciences and Consumer Products businesses. He has held top management roles in the life sciences space in companies like Shantha Biotech (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. Shantha Biotech a biosimilar and vaccine company was eventually acquired by Sanofi for around $ 800 MN in 2010. He has been a part of significant revenue growth and significant value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.
He has held CEO roles in Emami and Cavinkare, CPG companies, growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company's value went up by 4 times within 3 years. The momentum thus created, has made Emami a large market cap FMCG company in India now. During early part of his career, he created some very successful brands in Cavinkare, a leading CPG company from India, and built the organization with a 10X revenue increase in 6 years’ time and that early momentum has made Cavinkare one of the established Consumer product companies in India. He comes with core strengths in Strategy, Innovation, Marketing, Organization building, Finance, M&A and Governance. He has been an integral part of many industrial forums in Life sciences and CPG business.
Contact Information: email@example.com
Dr. Bhaskar Chaudhuri currently works with Frazier Healthcare as an Operating Partner. Previously, Dr. Chaudhuri served as the President of Valeant Pharmaceuticals International through the end of 2010. He joined Valeant through the Company’s acquisition of Dow Pharmaceutical Sciences, Inc. in late 2008, where Dr. Chaudhuri served as President and Chief Executive Officer. Dr. Chaudhuri serves on the board of Silvergate Pharmaceuticals.
Before joining Dow, Dr. Chaudhuri worked at Mylan Pharmaceuticals in different capacities including Executive Vice President of Scientific Affairs (Bertek Pharmaceuticals, a subsidiary of Mylan Laboratories) and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri joined Mylan through the acquisition of Penederm Inc., where he was the Vice President of Research and Development.
Dr. Chaudhuri has over 20 years of experience in pharmaceutical management and currently also serves on the Board of two companies. He holds a Doctorate in Physical Pharmacy, a Master of Science in Industrial Pharmacy and a Bachelor’s of Science in Pharmacy.
A career banker with 40 years’ experience in domestic and international banking, Mrs. Ranjana Kumar has been chairman of Indian Bank, Canara Bank and National Bank for Agriculture and Rural Development (NABARD). Most recently, she served as India's Chief Vigilance Commissioner in the Central Vigilance Commission.
Mrs. Kumar was instrumental in transforming the Indian Bank from a loss-making entity to a viable business, and was named 'India's Turnaround Queen' by The Economist for this achievement. Prior to Indian Bank, she was chairman of Canara Bank, and also served as CEO of Bank of India's US operations from 1995-99.
In 2002, Business Standard named Mrs. Kumar 'Banker of the Year', and in 2013, she received the Lifetime Achievement Award from Business World magazine.
Kumar Shiralagi has a 10-plus year track record of managing high-performing investments and exits. He is a managing director at Kalaari Capital, where he serves on ten company boards and has been involved with more than 25 companies - advising investments, serving on boards, and managing exits. From 2003 to 2007, he was Country Director of Intel Capital India. He is a Senior Member of IEEE and a Charter Member of TiE. He has published more than 60 technical papers, holds 23 U.S. patents, and co-founded Lytek Corporation, a semiconductor laser manufacturer.
Kumar graduated with an engineering degree from NIT Karnataka and a PhD in electrical engineering from Arizona State University. He also holds an MBA from the Thunderbird School of Global Management.
Rajiv Maliwal, 54, is the Founder and Managing Partner of Sabre Partners, a private equity firm which manages over half a billion dollars focusing on financial services, healthcare and infrastructure. He is best known for having pioneered and successfully implemented a unique private sector solution for ailing and stressed financial institutions in India (e.g. Centurion Bank, Lord Krishna Bank etc.), and more recently, in spearheading growth of healthcare in India through some innovative financing structures.
Prior to founding Sabre Partners in 2002, Rajiv was at Standard Chartered PLC as Global Head of Private Equity. He raised a $300m fund, built a global team and invested internationally with a focus on financial services and technology. Between 1993 and 1998, he was with Goldman Sachs, Hong Kong and JP Morgan, Singapore and was responsible for setting up and growing the investment banking and securities businesses for them in South East Asia and India. He established a JV for both these firms in India with domestic partners (Goldman Sachs/Kotak Mahindra JV and JP Morgan/ICICI JV), led many M&A, Equity and Debt underwritings and originated several private equity investments. Prior to 1993, Rajiv was with Citibank, where he was responsible for corporate and investment banking in Western India.
Rajiv graduated with an MBA from Indian Institute of Management, Bangalore in 1985 and holds a Bachelor of Engineering (Hons) degree in Mechanical Engineering from BITS, Pilani. He was awarded the IIM Bangalore, Distinguished Alumni Award in 2012. He sits on the board of several companies in India and globally. He is a member of the Board of Governors of IIM, Bangalore and was a member of Stanford Parents Advisory Board for 4 years. He is a frequent speaker at a number of educational institutions and forums internationally on entrepreneurship and regularly mentors start-ups. He is also closely associated with two not-for-profit healthcare initiatives in India in the fields of mental health and eye-care.
Alan Rosling founded Griffin Growth Partners, a consulting business focused on assisting international companies with Asian strategy. He has advised a large number of
international clients on growth strategies for the region as well as Indian companies on internationalisation. Alan also is co-founder and a Director of Kiran Energy, one of India’s leading independent solar power producers.
He is a Non Executive Director of Coats Plc and LNGaz, a Canadian small-scale LNG company which he co-founded. LNGaz has entered a Joint Venture with Stolt-Nielsen to develop an LNG facility in Quebec. He is also Senior Advisor to Navam Capital, an early stage technology venture fund.
Alan was an Executive Director of Tata Sons Limited for five years from 2004 and was the Director responsible for internationalising the Tata Group. From 1998 to 2003 he was Chairman of the Jardine Matheson Group in India. His earlier career included the Policy Unit at No.10 Downing Street; Strategy Director at United Distillers, CEO of a division of Courtaulds Textiles and S.G. Warburg.
Alan was educated at Cambridge University and the Harvard Business School.
Copyright © 2015 Vyome Biosciences. All rights reserved.